Citation Impact
Citing Papers
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
2009
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
2010
In vivo imaging of hydrogen peroxide production in a murine tumor model with a chemoselective bioluminescent reporter
2010 StandoutNobel
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production
2005 StandoutNobel
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
Strategy for Dual-Analyte Luciferin Imaging: In Vivo Bioluminescence Detection of Hydrogen Peroxide and Caspase Activity in a Murine Model of Acute Inflammation
2013 StandoutNobel
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Membrane-Type I Matrix Metalloproteinase-Dependent Regulation of Rheumatoid Arthritis Synoviocyte Function
2010
Neutrophil MMP-9 Proenzyme, Unencumbered by TIMP-1, Undergoes Efficient Activation in Vivo and Catalytically Induces Angiogenesis via a Basic Fibroblast Growth Factor (FGF-2)/FGFR-2 Pathway
2009
Hallmarks of Cancer: The Next Generation
2011 Standout
HLF/HIF-2α is a key factor in retinopathy of prematurity in association with erythropoietin
2003
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
2001
Tumour–host interactions: implications for developing anti-cancer therapies
2006
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
2012
Adult pancreatic β-cells are formed by self-duplication rather than stem-cell differentiation
2004 StandoutNature
Clinical translation of angiogenesis inhibitors
2002 Standout
Wound repair and regeneration
2008 StandoutNature
Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: Contrasting, overlapping and compensatory functions
2009
Tumor angiogenesis: past, present and the near future
2000
The role of myeloid cells in the promotion of tumour angiogenesis
2008
Proliferation, cell cycle and apoptosis in cancer
2001 StandoutNature
Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma
2001
Mast cells and angiogenesis
2002
Angiogenesis in cancer and other diseases
2000 StandoutNature
Multiple myeloma
2000 Standout
The Pathogenesis of Rheumatoid Arthritis
2011 Standout
Angiogenesis in health and disease
2003 Standout
Role of the N-terminal Catalytic Domain of Angiotensin-converting Enzyme Investigated by Targeted Inactivation in Mice
2004 StandoutNobel
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
2007 Standout
Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells
2002 StandoutNobel
Age-dependent Defect in Vascular Endothelial Growth Factor Expression Is Associated with Reduced Hypoxia-inducible Factor 1 Activity
2000 StandoutNobel
Putting tumours in context
2001 Standout
Integrins in angiogenesis: multitalented molecules in a balancing act
2003
Protein degradation and protection against misfolded or damaged proteins
2003 StandoutNature
Regulation of angiogenesis by hypoxia: role of the HIF system
2003 StandoutNobel
Angiogenesis-dependent diseases
2001
Angiogenesis in life, disease and medicine
2005 StandoutNature
Macrophage Responses to Hypoxia
2005
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
The microenvironment of the tumour–host interface
2001 StandoutNature
Immunity, Inflammation, and Cancer
2010 Standout
‘Accidental’ anti-angiogenic drugs
2000
Erythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic Retinopathy
2005
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
2007
Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone
2014 StandoutNature
Microenvironmental regulation of metastasis
2008 Standout
Thalidomide
2004
Sox18 induces development of the lymphatic vasculature in mice
2008 StandoutNature
The role of erythropoietin in regulating angiogenesis
2004
Multiple myeloma: evolving genetic events and host interactions
2002
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
1999 Standout
The proteasome: a suitable antineoplastic target
2004
Angiogenesis is an early event in the generation of myc-induced lymphomas
2000
Hypoxia-inducible Factor-1 Deficiency Results in Dysregulated Erythropoiesis Signaling and Iron Homeostasis in Mouse Development
2006 StandoutNobel
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
2000
Macrophage biology in development, homeostasis and disease
2013 StandoutNature
Oxygen Sensing, Homeostasis, and Disease
2011 StandoutNobel
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma
2010
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
2007 StandoutNature
The role of pericytes in blood-vessel formation and maintenance
2005
Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches
2001
Angiogenesis as a therapeutic target
2005 StandoutNature
Novel Role of NADPH Oxidase in Angiogenesis and Stem/Progenitor Cell Function
2009
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
2001
Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy
2015 StandoutNobel
Angiogenesis Research: Guidelines for Translation to Clinical Application
2001
Recent major improvement in long-term survival of younger patients with multiple myeloma
2007
Matrix Metalloproteinase 2-Integrin αvβ3 Binding Is Required for Mesenchymal Cell Invasive Activity but Not Epithelial Locomotion: A Computational Time-Lapse Study
2008
Defective carotid body function and impaired ventilatory responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1α
2002 StandoutNobel
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
2010
Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
2010
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Targeting the bone marrow microenvironment in multiple myeloma
2014
Peripheral Blood “Endothelial Progenitor Cells” Are Derived From Monocyte/Macrophages and Secrete Angiogenic Growth Factors
2003 Standout
Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
2000
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
2010
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
2001
Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent
2000
Reactivation of Hepatic EPO Synthesis in Mice After PHD Loss
2010 StandoutScienceNobel
Hearts From Rodents Exposed to Intermittent Hypoxia or Erythropoietin Are Protected Against Ischemia-Reperfusion Injury
2003 StandoutNobel
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
2009
Erythropoietin both protects from and reverses experimental diabetic neuropathy
2004
Vascular tumors in livers with targeted inactivation of the von Hippel–Lindau tumor suppressor
2001
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma
2009
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
2000
Progress and Potential for Regenerative Medicine
2006
Synergistic effect of HIF-1α gene therapy and HIF-1-activated bone marrow-derived angiogenic cells in a mouse model of limb ischemia
2009 StandoutNobel
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Multiple Myeloma
2011 Standout
Nitric oxide prevents axonal degeneration by inducing HIF-1–dependent expression of erythropoietin
2011 StandoutNobel
Angiogenesis in Endocrine Tumors
2003
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Erythropoietin receptor signalling is required for normal brain development
2002
Genes Expressed in Human Tumor Endothelium
2000 StandoutScience
The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo
2003
Inhibition of the oxygen sensor PHD2 in the liver improves survival in lactic acidosis by activating the Cori cycle
2015 StandoutNobel
Works of Roberto Ria being referenced
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
2008
Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma
2009
Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin’s lymphomas
1999
Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
1999
Erythropoietin as an angiogenic factor in gastric carcinoma
2003
Mast cell contribution to angiogenesis related to tumour progression
2004
Characterization of Mitochondrial and Extra-mitochondrial Oxygen Consuming Reactions in Human Hematopoietic Stem Cells
2005
Cross-talk Between Hematopoiesis and Angiogenesis Signaling Pathways
2002
Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis
1998
Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts
2002
An experimental study in the chick embryo chorioallantoic membrane of the anti-angiogenic activity of cyclosporine in rheumatoid arthritis versus osteoarthritis
2000
A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma
2004
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets
2011
Role of Hematopoietic Growth Factors in Angiogenesis
2001
Bone Marrow Angiogenesis and Plasma Cell Angiogenic and Invasive Potential in Patients with Active Multiple Myeloma
2001
Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine
1999
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
2002
Salvage Therapy With Thalidomide In Patients With Advanced Relapsed/Refractory Multiple Myeloma
2002
Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma.
2002
A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients
2008
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.
2003
Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo
1999
Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas
2000
Angiogenesis extent and expression of matrix metalloproteinase‐2 and ‐9 correlate with upgrading and myometrial invasion in endometrial carcinoma
1999
Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma
1999
Multiple Myeloma Macrophages: Pivotal Players in the Tumor Microenvironment
2013
Role of basic fibroblast growth factor in the formation of the capillary plexus in the chick embryo chorioallantoic membrane. An in situ hybridization, immunohistochemical and ultrastructural study.
1998
Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma
1999